Search alternatives:
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
longer decrease » linear decrease (Expand Search), largest decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
Showing 21 - 40 results of 20,910 for search '(( significant case based ) OR ( significantly ((longer decrease) OR (larger decrease)) ))', query time: 0.78s Refine Results
  1. 21
    Intermittent Heat Shocks Can Reduce Methanogenesis and Increase Generation of Longer-Chain Volatile Fatty Acids in Anaerobic Bioreactors

    Intermittent Heat Shocks Can Reduce Methanogenesis and Increase Generation of Longer-Chain Volatile Fatty Acids in Anaerobic Bioreactors by Hezhou Ding (14242293)

    Published 2024
    “…All HS temperatures significantly reduced CH<sub>4</sub> production (70–90%) without decreasing VFA production. …”
    Save to List
    Saved in:
  2. 22
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 23
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 24
    S1 Data -

    S1 Data - by Makda Abate Belew (14271673)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 25
    Psychosocial and behavioural characteristics of study participants.

    Psychosocial and behavioural characteristics of study participants. by Makda Abate Belew (14271673)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 26
    Sociodemographic characteristics of study participants.

    Sociodemographic characteristics of study participants. by Makda Abate Belew (14271673)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 27
    Bivariate and multivariable logistic regression analysis results.

    Bivariate and multivariable logistic regression analysis results. by Makda Abate Belew (14271673)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 28
    Clinical characteristics of study participants.

    Clinical characteristics of study participants. by Makda Abate Belew (14271673)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 29
    Significant genes identified in the gene-based test with GWAS summary data.

    Significant genes identified in the gene-based test with GWAS summary data. by Samantha Gonzales (8798435)

    Published 2025
    Save to List
    Saved in:
  10. 30
    Longer treatment is associated with increased post-rebound setpoint viral level.

    Longer treatment is associated with increased post-rebound setpoint viral level. by Mykola Pinkevych (125551)

    Published 2023
    Save to List
    Saved in:
  11. 31
    Phase 2 significant effects.

    Phase 2 significant effects. by Wendy C. Crone (2262169)

    Published 2023
    Save to List
    Saved in:
  12. 32
    Phase 1 significant effects.

    Phase 1 significant effects. by Wendy C. Crone (2262169)

    Published 2023
    Save to List
    Saved in:
  13. 33
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 34
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 35
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 36
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 37
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 38
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 39
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 40
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: